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Novelty Statement: 
 Closed loop technology has specific psychosocial benefits supporting 
optimal self-management in adults with type 1 diabetes 
 Advances in technology are associated with greater usability with further 
development work necessary to improve connectivity  
 Future research is required to determine the holistic impact of closed loop 
as a realistic therapy choice for people with type 1 diabetes
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Abstract: 
Aim: to explore 1) psychosocial experiences of closed loop technology and 2) 
compare ratings of closed and open loop technology for adults with type 1 
diabetes taking part in a randomized crossover study. 
Methods:  Adults age >18 years on insulin pump therapy were recruited to 
received real-time continuous glucose monitoring (CGM) with overnight 
closed-loop or real-time CGM alone (open loop) followed by the alternative 
treatment randomly, at home for 4-weeks unsupervised. Participants were 
invited to share their views in semi-structured interviews. Impact of the closed 
loop technology, positive and negative aspects of living with the device 
overnight, alongside hopes and anxieties were explored. 
Results: Participants: 24 adults, mean age 43(SD 12), 54% male.  Interview 
duration 12-46 minutes (mean 26 minutes).  Content and thematic analysis 
revealed key positive themes: Improved blood glucose control (n=16); 
Reassurance/reduced worry (n=16); Improved overnight control leading to 
improved daily functioning and diabetes control (n=16); Improved sleep (n=8).  
Key negative themes: Technical difficulties (n=24); Intrusiveness of alarms 
(n=13); Size of equipment (n=7). Twenty participants would recommend the 
closed loop technology.  
Conclusions: Closed loop has positive effects when it works in freeing 
participants from the demands of self-management.  The downside for those 
who had more negative views was generally down to technical difficulties 
particularly around the pump and ‘connectivity’ which should hopefully 
improve.  Future research should continue to explore acceptability as a 
realistic therapy option, taking account of user concerns as new systems are 
designed. Failure to do this may reduce the eventual utility of new systems.  
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Background 
Closed loop technologies, sometimes referred to as an artificial pancreas (AP), 
are developing rapidly with successful diabetes camp [1] and at 
home/outpatient trials [2-6].   Closed loop systems have demonstrated clinical 
efficacy resulting in tighter overnight glycaemic control without increased 
frequency or severity of hypoglycemia [3,4].   With the potential to provide a 
realistic treatment option for people with type 1 diabetes (T1DM), the usability 
and impact on psychosocial outcomes will be crucial factors in determining 
the realization of benefit from use of this technology [7]. 
 
Maintenance of optimal glycaemia overnight is particularly challenging, with 
nocturnal hypoglycaemia common, representing a critical problem in the 
management of type 1 diabetes (T1DM) and causing heightened anxiety 
affecting psychosocial functioning [8].  The risk of hypoglycaemia represents a 
major obstacle to the achievement of optimal blood glucose levels  [9].  Early 
overnight closed loop research has show positive results in achieving optimal 
glycaemia without increased risk or frequency of hypoglycaemia for 
adolescent participants [3,4].    
 
The current open-label, multicentre, randomized crossover study recruited 
participants from three centres in the UK.  Participants aged 18 years or older 
with type 1 diabetes were randomly assigned to receive four weeks of 
overnight closed-loop insulin delivery (using a model-predictive control 
algorithm to direct insulin delivery), then four weeks of insulin pump therapy 
with real-time continuous glucose monitoring (open loop phase), or vice versa.  
The primary outcome was time spent in the target glucose range of 3.9-8.0 
mmol/L between midnight and 0700 hours.  Analyses were by intention to 
treat [4]. 
 
The purpose of this sub-study, alongside the main trial, was to explore 1) 
psychosocial experiences of closed loop technology and 2) compare ratings 
of closed and open loop technology for adults with type 1 diabetes taking part 
in a randomized crossover study. 
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Methods and Participants 
The main aims and methodology of the trial have been reported in detail 
elsewhere [4].  In brief, alongside efficacy and safety outcomes of closed loop 
technology in this open-label, single-centre, randomised two period cross-over 
study (12 completing closed loop phase first), the utility of the technology was 
evaluated.  Inclusion criteria were type 1 diabetes (WHO criteria), C-peptide 
negative, aged 18 years or older, insulin-pump therapy for at least 3 months, 
knowledge of insulin self-adjustment, undertaking of glucose self-monitoring 
at least four times daily, and HbA1c of 10% (86 mmol/mol) or lower.  
Exclusion criteria were established nephropathy, neuropathy or proliferative 
retinopathy, total daily insulin dose of 2.0 U/kg or greater, regular use of 
continuous glucose monitoring within 1 month before enrolment, severe visual 
or hearing impairment, pregnancy, or breastfeeding.  The study protocol was 
approved by the East of England Central Cambridge Ethics Committee.  The 
study included a mixed methods approach, using psychosocial questionnaires 
and semi-structured interviews to evaluate participants’ perceptions of lifestyle 
change, diabetes management and fear of hypoglycaemia.   
 
Questionnaire Data 
At study entry and again at the end of two interventions, each participant 
completed the Diabetes Technology Questionnaire (DTQ). This is a 30-item 
measure of the impact of, and satisfaction with, technological tools that may 
be used in the management of T1DM [8].  Participants were asked to rate 
their agreement or disagreement with statements regarding the specific 
complement of diabetes technologygies in use at that measurement point (ie, 
real time continuous glucose monitoring alone or meter, pump, continuous 
glucose monitor, closed loop with real time continuous glucose monitoring AP). 
Individual items are scored separately for each of the two columns of 
response options, yielding separate total scores for “Is this a problem now?” 
(Current) and “How has it changed compared to your treatment before the 
study?” (Change). The DTQ was administered at baseline and at the end of 
the two 28-day crossover periods.  Statistical analysis was conducted using 
SPSS (version 21). Analysis was conducted using descriptive statistics and 
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repeated measures including t-test and ANOVA with a statistical significance 
threshold of 0.05%.  Statistical analysis was conducted using SPSS (version 
21). 
The DTQ yields separate scores for ‘Current’ (How much is this a problem 
now?) and ‘Change’ (How has it changed compared to before the study?) 
subscales. At Baseline, only the “Current” items were administered, while at 
the conclusion of each crossover period, both the “Current” and “Change” 
items were administered. After reverse scoring of some items, higher scores 
are indicative of more favourable satisfaction and impact ratings of the 
technology. Based on participant responses in the present study, internal 
reliability (Cronbach’s Alpha Coefficient) remained above 0.91 for the DTQ 
“Current” items and above 0.94 for the DTQ “Change” items throughout the 
study. Previous unpublished data from a sample of 115 adolescents and 
parents yielded similar psychometric data.  
For the present study, the DTQ was modified to include a 9-item “User 
Friendliness” section for each of four possible technological components of 
the participants’ diabetes regimens (glucose meter, insulin pump, continuous 
glucose monitor, closed loop insulin delivery system). Participants rated the 
complete package of technology they had been using as well as each 
component that was part of their current regimen along each dimension of 
user friendliness on a 5 point scale with 1 = “Terrible” and 5 = “Excellent”. 
Semi-Structured Interviews 
Semi-structured interviews to explore participants’ perceptions of the impact 
of the technologies on their experiences were designed in collaboration with 
the clinical research team.  Factors including lifestyle change, diabetes 
management, safety and impact on their ability to carry out their usual daily 
routines were discussed.  The interview schedule was then piloted on four 
potential participants for usability, relevance, and acceptability. These 
participants were not included in the study. The feedback was positive with 
minor revisions suggested, and the interview schedule was revised in line with 
this. All participants taking part in the study were invited to participate in the 
interview study and all elected to do so. 
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On completion of each intervention, participants were invited to partake in an 
audio-recorded telephone interview conducted by KDB. All interviews were 
conducted within 2 weeks of the end of the trial.  Audiotapes were transcribed 
with all identifying details removed.   Following transcription, KDB and AJY 
performed independent thematic analyses, reading each participant's 
interview in full before performing cross-comparisons to identify continuities 
and differences between accounts. This analysis was used to develop a 
coding framework which captured original research questions and emerging 
findings [11]. 
Content analysis focused on the number/frequency of ‘instances’, their 
context, meaning and whether they were common across participants.  Free 
text analysis concentrated on identifying key themes arising with a view to 
understanding the experiences of participants, exploring connections between 
themes and identifying how the technology affected everyday living and 
factors important to quality of life in ways that are important to participants.  
 
Results 
 
Twenty-four adults, mean age 43 (SD 12) years, 54% male, HbA1c 65 (9) 
mmol/mol [8.1%(0.8), BMI 26.0 (3.5) kg/m2, duration of diabetes 29 (11) years, 
participated in the interviews.  Interview duration ranged from 12 to 46 
minutes (mean 26 minutes). Twenty-two participants completed the trial, two 
participants were classified as having a shortened study period (where the 
closed loop technology safety mechanism instigated reversion to routine 
insulin pump therapy), one of whom would have preferred to continue.  All 
data are reported collectively.  
 
Questionnaire Data:  DTQ data at one or more measurement points were 
missing for three participants. Mean DTQ item scores during each phase of 
the study are shown in Table 1 at Baseline (DTQ “Current” items only) and 
after the Closed Loop and Open Loop phases (DTQ “Current” and “Change” 
items). The mean item scores were all above 3.0, indicating overall favourable 
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ratings of impact of and satisfaction with the diabetes technology just recently 
used by the participants. Although the DTQ Current item scores appeared to 
be higher (more favorable) after the Open Loop phase, these scores did not 
differ significantly between any of the three conditions. The same was true of 
the comparison DTQ “Change” scores between the Closed Loop and Open 
Loop conditions. Two-tailed t-tests for related means comparing DTQ 
“Current” total scores at Baseline vs Open Loop (t = -1.48; p < 0.16), 
Baseline vs Closed Loop (t = 0.47; p < 0.65), and Closed Loop vs Open 
Loop (t = -1.24; p < 0.23) all failed to reach statistical significance. The 
same was true of the comparison of DTQ “Change” total scores 
following the Closed Loop and Open Loop phases (t = -1.18; p < 0.26). 
 
(Insert Table 1 about here) 
 
User Friendliness ratings of each technological component of participants’ 
current diabetes regimens were evaluated by examining the percentages of 
responses in the “Good” or “Excellent” categories. The most important of 
these results, presented in Table 3 2 below, concern participants’ ratings of 
the closed loop insulin delivery system after the Closed Loop phase of the 
study. The results show that participants were least satisfied with the use of 
the closed loop system during physical activity and bathing and regarding 
appearance issues created by use of the system (mean ratings in the “Poor” 
range). The participants were most satisfied with the closed loop system 
regarding ease of start-up and calibration, the instructions, manual and 
technical support that were provided, and performance accuracy/reliability 
(mean ratings in the “Good” range). None of the items yielded a mean rating 
above 4 (Good) on the 5–point response scale. 
 
(Insert Table 2 about here) 
 
These results also indicated relatively fewer “Good” or “Excellent” ratings of 
the insulin pumps used during the Open (27.8%) and Closed (29.4%) Loop 
phases compared to baseline (77.2%).   
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Eight participants directly spoke about their improved sleep as a consequence 
of using the closed loop system.  Reassurance and peace of mind associated 
with the closed loop technology were frequently cited as benefits (n=16).  
Being able to worry less about diabetes and blood glucose levels, as well as 
the security of knowing that the technology was ‘taking over for a while’ 
contributed to this reassurance. 
 
Sixteen participants directly commented on having improved blood glucose 
levels as a result of using the closed loop system, reporting that ‘waking up on 
a good number’ contributed to improved blood glucose control into the 
following day, providing a ‘better start’ to the day rather than waking up and 
immediately having to deal with a hypo or hyperglycaemia. 
 
(Insert Table 3 about here) 
 
In response to the question ‘what would you change about the closed loop 
system?’ thirteen participants said ‘the equipment’, specifically, six would 
make it smaller and seven would make it more portable, including increasing 
the Bluetooth range, i.e. improving connectivity. 
 
In response to ‘What was the impact on your daily life?’, eight participants 
reported the closed loop could ‘do a better job than I could’ reporting that 
having improved nocturnal glycaemic level meant they had a better day.  Five 
reported the positive impact of improved blood glucose control, saying they 
‘felt better’, ‘worried less’ and ‘had increased confidence’.  Negative impacts 
reported were the system being ‘inconvenient’ (n=4) and it ‘restricting 
movement’ (n=1), with another participant saying the whole experience was 
‘really hard’. 
 
Twenty participants would recommend the closed loop technology to a friend 
with type 1 diabetes, one participant couldn’t answer this question and three 
would not recommend it. 
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When asked for their preference between closed loop and CGM, twelve 
participants chose the closed loop system, four the CGM, two did not answer 
and six participants were unable to provide a preference for a number of 
reasons: 
 ‘no preference – Closed Loop took a little more effort’ 
 ‘Closed Loop isn’t quite there yet…it required more time’ 
 ‘Open Loop [CGM] you are still controlling yourself…Closed Loop took 
more effort’ 
 ‘Open Loop [CGM] is a useful system…takes more time. Closed Loop 
takes control away…it was quite liberating’ 
 
These responses are diametrically opposite in the sense that both quotes 
refer to the autonomy of the Closed Loop, with one person finding this 
problematic and the other really liking it. 
 
Key Positive Experiences 
Table 3 illustrates the positive comments received. The enthusiasm and 
strength of feeling expressed by some participants about their experience of 
the Closed Loop were significant.  ‘Brilliant’, ‘sad to finish’, ‘felt half way 
human’, ‘I was a nicer person to be around’, ‘I was more effective, more 
productive’ and ‘I felt normal’ were all comments made by participants.  None 
of the participants regretted taking part in the trial and all had something 
positive to say about their experience of being involved.  However, three 
participants who completed the trial felt that participation had been 
challenging at times, saying ‘it took over my life’ (005), “I was sick to death of 
it’ (018) and “it was fragile, laborious and had a major impact on my routine.” 
(023).   
 
Potential reduction of long-term complications (via improved blood glucose 
control overnight) were reported by three participants.  ‘Improved health’, 
‘more energy’, feeling ‘liberated’ and ‘generally feeling better’ were cited as 
benefits by participants.  Similarly, ‘improved sleep’ was reported by six 
participants contributing to general feelings of well-being.  One participant 
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commented on the change in their partner’s attitude towards their diabetes 
saying ‘it made him [partner] much more aware of how difficult it is controlling 
diabetes …. made him much more caring’ (018) 
 
Furthermore, reassurance, reduced worry and peace of mind were associated 
with using the closed loop (n=16), with a better understanding of diabetes 
(n=3) and seeing how ‘it’ responded to different situations was helpful (n=1).  
Nineteen participants felt safe with the device, particularly once their initial 
anxiety about whether it would perform on the first day or two, and were 
confident that it “was OK”.  See table 3 for detail.  
 
The concept of the technology and the prospect of ‘how good it could be’ in 
the not too distant future, moving towards a fully automated system and 
associated possibilities was reported as a benefit by nine participants (n=9), 
something that was expressed by parents of adolescents taking part in the 
previous study.  Several participants said that they had taken part to help 
‘further the cause’ of diabetes research and hoping to benefit other people as 
well as themselves in the future.  There was also widespread 
acknowledgement that this is cutting edge research and so some teething 
difficulties were inevitable. 
 
(Insert table 4 about here) 
Key Negative Experiences 
Table 4 illustrates the key negative experiences reported. 
 
(Insert Table 4 about here) 
 
All participants reported having experienced some technical or usability 
difficulties with the equipment, however these were most often associated 
with the insulin pump and continuous glucose monitor than with the Closed 
Loop technology itself.  Common problems included connection difficulties, 
poor battery life, sensors not sticking very well or getting in the way /being too 
large.  See table 4 for detail. 
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The alarms were also a problem for several participants (n=13), particularly 
when they became intrusive by waking up other family members or caused 
repeated sleepless nights.  Feelings of powerlessness were reported in terms 
of the alarm sounding, corrective action being taken promptly but then the 
alarms continuing to sound every 20 minutes (or so) as blood glucose levels 
were returning to a safe range.  Interestingly, participants did not distinguish 
between ‘real’ alarms or ‘false’ alarms, so it is not possible to know whether 
the alarms were always appropriate.  Two participants did however report that 
the alarms were a positive aspect of the technology because they gave them 
a greater awareness of hypo- and hyper- glycaemia and were able to act 
quickly to treat them. 
 
Seven participants commented on the size of the equipment, specifically the 
lack of portability of the laptop, the size of the sensors, having to carry so 
many things but lacking somewhere to put them.  For those participants who 
used both first generation and second generation sensors, the reduced size of 
the second generation sensors was reported favourably. 
 
Three participants reported the inconvenience of using the equipment, finding 
it hard to fit it into their lifestyles.  Another participant reported increased 
anxiety because of the technology, with a further three participants reporting 
more episodes of hypoglycaemia than usual whilst on the closed loop.  For 
one of these, it ‘knocked my confidence’.  
 
Discussion 
The impact of the tested Closed Loop technology was positive for most 
participants’ experience (n=21), outweighing reported downsides which were 
often described as ‘teething’ problems with the technology.   
 
Closed Loop technology represents cutting edge technological research in the 
treatment of type 1 diabetes, with technological advancements facilitating a 
progression to home-based trials.  There is scant evidence however on 
whether it will meet people’s needs in the context of usability and 
psychosocial functioning.  Alongside biomedical and cost-effectiveness 
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benefits, the technology must be usable, safe and beneficial from a 
psychosocial perspective if people are going to be able to embrace it as a 
realistic therapy option.   
 
Participants’ impact and satisfaction ratings after use of Closed Loop or Open 
Loop technology, as measured by the DTQ, revealed that, overall, participants 
were moderately favourably disposed toward both insulin delivery systems. Of 
the 30 DTQ items, 20 differences scores favored Closed Loop, 7 difference 
scores favored Open Loop and 3 difference scores were 0, favoring neither 
alternative. 
 
Analysis of User Friendliness of the Closed Loop system revealed 
moderately positive opinions of the technology except for items measuring 
appearance concerns and difficulties using the system during physical 
activity and bathing. Otherwise, the usability ratings were moderately positive 
(in the “Good” range), revealing aspects of the Closed Loop system needing 
further improvement.  This was also reflected in the interviews, where 
participants reported challenges transferring to the study insulin pump which 
was different to the one they usually wore. 
 
 
Key themes, both positive and negative, were similar to that reported for 
adolescents with type 1 diabetes [11], with widespread optimism for future 
technological developments and potential availability commercially in the near 
future.  Usability challenges perhaps had a greater impact on daily living than 
those reported by adolescents, contributing to less enthusiasm for the 
technology than was reported by parents in previous research.  Participants in 
the current study reported hoping the closed loop would be available for 
younger generations with type 1 diabetes and were thinking about potential 
availability as their own children grew up. 
 
Technological advances in diabetes management have been rapid over 
recent years and have been met with mixed reviews. Insulin pump therapy 
and continuous glucose monitoring devices have been both positively and 
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negatively associated with quality of life [12,13].  Whilst benefits of these 
technologies are widely reported, the reality of having to live with a device 
constantly over a period of time can be challenging.  It could be argued that 
participants in closed loop research are ‘highly motivated’ [2] and perhaps not 
representative of the wider T1DM population.  Thus it is important to consider 
that interruptions to daily living and the requirement to dedicate more time 
than desired on diabetes self-management take their toll on the lived 
experience and quality of life.  Technological development should ensure the 
psychosocial impact of devices is fully considered. 
 
Limitations of the current study include the low participant numbers and the 
fact that the trial was powered on time spent in target glucose range, so 
lacked statistical power to detect significant differences in psychosocial 
functioning between the two arms.  Similar challenges have been found in 
previous research [5] where anxiety and quality of life was not assessed due 
to the short duration of the intervention.   The interviews were designed to add 
depth and psychosocial context to the biomedical results of the main trial and 
as such were not designed as a detailed qualitative evaluation that would 
have required considerably longer interviews and phenomenological analysis.  
 
Conclusions 
The development and refinement of closed loop technology is moving apace.  
Representing cutting edge therapy for the treatment of type 1 diabetes, the 
biomedical benefits are matched by psychosocial outcomes.  The additional  
information provided from the open loop technology was liked by participants 
however technical glitches were reported drawbacks.  The closed loop device 
has major positive effects when it works in freeing patients from some of the 
demands and challenges of self-management.  The downside for those who 
had more negative views was generally down to technical difficulties 
particularly around the pump and the ‘connectivity’ that should hopefully 
improve.  Future research should continue to explore the holistic acceptability 
of closed loop as a realistic therapy option and take account of user concerns 
as new systems are designed. Failure to do this may reduce the eventual 
utility of new systems.  
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Table 1. Mean (SD) DTQ scores for the Current and Change items at 
Baseline and following the Closed Loop and Open Loop phases of the study.  
DTQ Scores Baseline 
(n=22) 
Open Loop 
(n=19) 
Closed Loop 
(n=20) 
Current 3.66 (0.53) 3.89 (0.52) 3.63 (0.64)  
Change  3.22 (0.44) 3.24 (0.63) 
 
 
 
 
Table 2. Participants’ ratings of the closed loop insulin delivery system 
User Friendliness Item Mean SD 
System Size, Weight, Appearance, Fashion Issues 2.29 0.72 
Ease of Start-Up, Calibration, etc. 3.95 1.02 
Battery Life and Ease of Replacement 3.05 1.39 
Variety and Flexibility of Functions 3.44 1.29 
Instructions, Manual and Technical Support 3.95 0.81 
Screen Information and Reports 3.35 1.14 
Alarm Functions 3.38 1.20 
Use During Sports, Exercise, Bathing 2.00 1.28 
Accuracy and Reliability of Performance 3.79 1.03 
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Table 3: Key Positive Themes 
Theme and participant examples ID 
Reassurance/peace of mind 
“The reassurance, it was comforting knowing it was there” … “My 
blood sugars were more stable than they normally are”. 
“I went to bed confident that they were better than they normally 
would be”. 
“Not worrying about my blood sugars and feeling it was its 
responsibility, not mine”. 
022 
“I didn’t have to worry” 010 
“I didn’t go to sleep worrying about a hypo” 014 
“I didn’t need to worry as it looked after you” 016 
“You could wake up, look at this diagram of the profile of your blood 
sugar and it would be dead level, erm absolutely constant 
throughout the night and that makes you feel better”. 
006 
“It was pretty good …. It was the best I have had for several years”. 
“I didn’t go to sleep worrying about having a hypo or not waking up”. 
“I knew that it would correct this, it was like a break”. 
014 
“It was brilliant … it allowed me to stop worrying about a lot of things 
…” 
013 
General Positive Comments 
 
“In the 2 weeks I was using it, it was brilliant”. 
“The principle of it is wonderful [if it lived up to expectations]”. 
017 
“I didn’t realize how much better I could feel”.  
“I’ve never felt better in my adult life …. I felt normal, more fund to 
be around”. 
“It made me much more effective, more productive and much nicer 
to be around”. 
“I felt really emotional … like I was on the brink of something”. 
003 
“The whole thing was brilliant”. 
“When it finished I was really sad”. 
“Very impressed, I enjoyed it very much and wish it hadn’t stopped”. 
012 
“If I could get over my dislike of the pump, that would be the worse 
thing about it, it would be coming off it and giving the system back”. 
004 
“Once you got used to it, it was really good”. 007 
Better sleep 
“It did away with the intrusiveness and not having to wake up and 
check blood glucose levels” 
017 
“Better sleep pattern …When it worked it was fantastic … I had 8 
hours uninterrupted which is fantastic”. 
009 
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“Better sleep” 011 
“You were in the morning at a good level to start with”. 
“You didn’t worry when you went to sleep because you knew it was 
going to look after you”. 
016 
Wake up in the morning feeling normal 020 
Improved blood glucose control 
 
“Better insight into controlled whole diabetes” 018 
“It managed to maintain blood glucose levels” 004 
“I only had one overnight hypo” 010 
“It was brilliant!  All conversations are ‘we don’t know what’s 
happening at night …. Now it’s good overnight and we don’t have to 
think about it.  I slept so much better.” 
“Knowing that for 8 hours a day, you have good control.” 
“There was nothing bad about the algorithm [but the equipment was 
still quite raw].” 
001 
“My blood glucose was perhaps better controlled”. 005 
“I was really impressed with how it stabilized my blood sugar, it was 
pretty much spot on”. 
011 
“Waking up in the morning and seeing your blood sugars in a 
straight line for about 12 hours which was fantastic”. 
“I can’t describe that feeling but it was brilliant.  It really is amazing”. 
019 
“My sugars were a lot better in the morning … it does what it says 
on the tin”. 
“The technology is coming forward and research is coming forward 
…. There will be solutions to the issues”. 
008 
“The concept .. moving towards an artificial pancreas optimizing 
people’s sugar controls to improve the levels to avoid high 
readings”. 
“It was generally doing at least as good if not a better job than I 
would be doing myself”. 
002 
“Wake up with perfect blood glucose levels, good start to the day” 021 
Improved blood glucose control overnight led to improved 
daytime control 
 
“I was impressed how it controlled things during the day” 013 
“Better during the day as it’s being controlled better” 015 
“Feeling better in the morning” 011 
“My control overnight almost all of the time was excellent.” 
“I would pretty much always wake up with a perfect blood sugar 
which was then a really good way to start your day”. 
021 
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Table 4: Key Negative Themes 
Theme and participant examples ID 
Alarms beeping frequently 
‘absolutely dreadful … sick to death of it’ 018 
‘It bleeped a lot at night, the alarms’ 015 
‘Alarming all the time’ 021 
‘Problems with the companion waking me up’ 005 
“The alarms …. Everybody knows”. 001 
“There were so many times when for a variety of reasons it kept 
me awake all night because it was alerting or it didn’t seem to 
work”. 
“The worst thing for me was not knowing whether what was 
happening was down to operator incompetence or the technology”. 
009 
“There were a couple of stressful moments … it was not as robust 
or resilient as I thought it would be”. 
“The alarms were very intrusive”. 
003 
“The alarms would go off [when setting up the system]”. 008 
“The alarms”. 
“The whole system is too big … you couldn’t walk around with it”. 
007 
“The alarms … connecting them altogether was a problem really” 
“I found it difficult with my shift patterns” 
“The equipment really …” 
015 
“It was awful … it wasn’t for me at all”. 
“The inconvenience in the evening, the bleeping just going off … 
its sleep deprivation for me” 
020 
“It got a bit confused .. it bleeped at night a couple of times and 
kept losing contact”. 
012 
Technical/Usability difficulties 
Problems with the hardware 018 
Connecting the devices together was a problem 015 
It kept losing contact 012 
“The calibration at night”. 007 
It’s noisy, technical setting it up and the range is too short 016 
“It’s too easy to turn off by mistake”. 004 
“I had a lot of trouble with the transmitter”. 
“The terrible row …” 
“The first week I felt sleep deprived”. 
005 
“The equipment wasn’t very easy to use” [talking mostly about 
CGM and pump] 
006 
“The noise from the hardware … the fan .. next to the bed”. 
“I was wary of it losing its connection”. 
010 
“I had to sleep very close to the thing which meant I didn’t have 
much room to move” 
016 
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“If I turned over the sensor was too far away from the CAD and it 
got detached which was the worse thing” 
“It’s quite restrictive” 
“The connectivity .. the blue tooth” 013 
“You feel a bit battered by the end of it … fit your whole life around 
a machine that isn’t working that well”. 
019 
Night-time hypos 
 
“Absolutely dreadful”. 
“I was really angry by the end of it … I had a lot of problems with 
the hardware”. 
“The whole thing overwhelmed me I have to say”. 
“You couldn’t image what was going to go wrong next” 
“Whilst I was on the Closed Loop … I was really worried because I 
kept going hypo” 
“I found it made me really anxious” 
018 
More night hypos on the Closed Loop 005 
Too big 
 
“Not very portable …. So much equipment you need to be using 
for the Closed Loop” 
011 
Needs to be smaller 014 
It’s bulky 016 
“.. limited by the actual technologies available …” 
“You have to be within reasonable range for the transmitter to work 
…” 
“All the communication between the algorithm and equipment …” 
002 
“Making it smaller would be the biggest thing” 014 
 
 
